What is the intramuscular (IM) dosage of Versed (midazolam)?

Intramuscular Midazolam Dosing

For acute seizure management in adults and children, administer midazolam 0.1 mg/kg IM (maximum 10 mg), which provides efficacy equivalent to IV lorazepam and is the preferred route when IV access is unavailable. 1

Standard IM Dosing by Clinical Indication

Acute Seizures (First-Line Indication)

• Initial dose: 0.1 mg/kg IM (maximum 10 mg single dose) 1
• Repeat dosing: May repeat the same dose every 5-10 minutes if seizures persist, allowing maximum of 2-3 repeat doses before escalating therapy 1
• Onset: Comparable efficacy to IV administration when IV access unavailable 1
• Critical requirement: Immediately administer a long-acting anticonvulsant (phenytoin/fosphenytoin or carbamazepine) after midazolam, as benzodiazepine redistribution causes seizure recurrence within 15-20 minutes 1

Procedural Sedation (Adults)

• Standard adult dose: 2-3 mg IM for patients aged 60-69 years 2
• Elderly patients ≥70 years: Use with extreme caution under continuous observation; excessive drowsiness occurred in 3% of patients regardless of weight, age, or ASA status 2
• Onset: Rapid sedation, anxiolysis, and anterograde amnesia within 15 minutes 2
• Peak effect: 20 minutes after IM injection 3

Preoperative Sedation

• Adults <60 years: 0.08 mg/kg IM (maximum 5 mg) 3
• Adults 60-69 years: 2-3 mg IM produces comparable effects to higher doses in younger patients 2
• Adults ≥70 years: Reduce dose; consider 1-2 mg maximum due to unpredictable excessive drowsiness risk 2

Critical Dose Reductions Required

Mandatory 20-50% Reductions

• Hepatic or renal impairment: Reduce dose by at least 20% due to decreased clearance 4, 1
• Concurrent opioid use: Reduce dose by at least 20% due to synergistic respiratory depression 4, 1
• Elderly patients (≥60 years): Reduce dose by 20-50% 4, 1
• H2-receptor antagonist use: Reduce dose due to 30% increased bioavailability 4, 1

High-Risk Populations

• Frail, hemodynamically unstable, or COPD patients: Maximum 0.5-1 mg IM 4, 5
• Patients receiving oral olanzapine: If midazolam must be used, maximum 0.5-1 mg IM with continuous pulse oximetry and immediate flumazenil availability 4

Safety Monitoring Requirements

Respiratory Depression Risk

• Timing: Can occur up to 30 minutes after administration, extending beyond apparent sedative duration 4, 5, 1
• Incidence: Approximately 1% of cases 1
• Monitoring: Continuous oxygen saturation and respiratory status monitoring required 1
• Reversal: Flumazenil must be immediately available, though it precipitates seizures and negates anticonvulsant effects 5, 1

Duration of Action

• Sedation: 1-4 hours after bolus administration 5
• Amnesia: Persists 80 minutes or longer after last dose 5
• Recovery position: Place patient on side to reduce aspiration risk 1

Common Clinical Pitfalls to Avoid

Seizure Management Errors

• Omitting long-acting anticonvulsant: Failure to administer phenytoin/fosphenytoin or carbamazepine immediately after midazolam increases seizure recurrence within 15-20 minutes 1
• Inadequate interval between doses: Must wait full 5-10 minutes to assess response before repeat dosing 1
• Premature escalation: Allow 2-3 repeat doses before calling emergency services 1

Dosing Errors

• Combining full doses with CNS depressants: Markedly increases respiratory depression risk without dose reduction 1
• Inadequate monitoring duration: Respiratory depression can manifest up to 30 minutes post-dose, requiring prolonged observation 4, 5, 1
• Underestimating elderly risk: Patients ≥70 years require continuous observation regardless of calculated dose 2

Special Considerations

• Paradoxical agitation: Occurs in approximately 6% of younger children 4, 1
• Pain at injection site: Common with IM administration, may persist up to 48 hours 3
• Flumazenil limitations: Half-life of 0.7-1.3 hours is shorter than midazolam's effects, creating resedation risk 5